By forming a new research project with other companies and universities we at Lundbeck now add yet another approach to our many different ways of trying to find new and better medicines to treat Parkinson’s disease and Alzheimer’s disease.
Named IMPRiND the new project, partly funded through EU’s Innovative Medicines Initiative (IMI), will investigate whether identifying targets modulating the mechanisms of propagation of aggregated proteins between cells could enable novel therapeutic approaches in Alzheimer’s and Parkinson’s disease.
Read the full release, here: IMPRiND
In lay man’s terms, the underlying hypothesis is that the process causing toxic proteins to spread in the brain and then kill neurons in itself is actually the root cause of the diseases. Hence our researchers are interested in both stopping the spreading and stopping the proteins from damaging the cells. The idea is that this would remove the cause of the symptoms thereby treating the diseases. It might be that if these processes can be stopped, it will treat several neurodegenerative diseases. However, as with other early research projects, there is a high risk that the hypothesis may not be substantiated.
The IMPRiND consortium brings together pharmaceutical companies and public research organisations from across Europe. Pharmaceutical partners are Lundbeck , Janssen Pharmaceutical NV (Belgium); Novartis (Switzerland), Servier (France), Eli Lilly (UK), AbbVie (Germany).
The academic institutions from across Europe include: University of Oxford (UK), University of Cambridge (UK), MRC Laboratory for Molecular Biology (UK), University of Dundee (UK), German Center for Neurodegenerative Diseases, University Medical Center Goettingen (Germany), VIB Center for the Biology of Disease (Belgium), University of Bordeaux (France), Centre National de la Recherche Scientifique (France), Aarhus Universitet (Denmark), Biomedical Research Foundation of the Academy of Athens (Greece) and the project management company SCIPROM (Switzerland).
The project runs until 2021 with a budget of around EUR 11m.